General Hospital Of Eleusina Thriasio

The General Hospital Of Eleusina Thriasio is applying cutting‑edge diagnostics and therapeutic tools to improve patient outcomes across several disease groups, with a focus on rapid biomarker assessment and targeted drug delivery.

• Biomarker‑guided early clarithromycin therapy for community‑acquired pneumonia
• Pancreatic stone protein (PSP) driven meropenem administration in the emergency department
• Rapid point‑of‑care testing to identify IFNγ‑driven sepsis endotypes
• Single‑day safety evaluation of a novel antimicrobial agent (OMN6) in ventilator‑associated pneumonia

Six active trials and seven investigators are leveraging advanced equipment to personalize treatment decisions.

Research at the site targets serious bacterial lung infections, including both community‑acquired and hospital‑acquired forms, aiming to test new antimicrobial strategies and immune‑modulating therapies.

• Emapalumab for IFNγ‑driven sepsis endotype
• Early meropenem intervention guided by PSP levels
• Safety and tolerability of OMN6 in hospital‑acquired bacterial pneumonia
• Adjunctive clarithromycin to prevent sepsis progression in pneumonia patients

The program emphasizes reducing mortality from resistant bacterial pathogens while evaluating novel monoclonal antibodies.

Trials focus on acute myocardial infarction, testing anti‑inflammatory approaches that may lower the incidence of future cardiac events.

• Ziltivekimab to reduce major adverse cardiovascular events after STEMI/NSTEMI
• IL‑6 pathway inhibition as a strategy to curb post‑infarction inflammation
• Evaluation of early anti‑inflammatory dosing schedules in heart attack patients

By integrating cardiovascular care with immunology, the hospital seeks to improve long‑term survival after heart attacks.

The centre investigates disorders where immune dysregulation drives disease, such as persistent symptoms after viral infection and hyper‑inflammatory sepsis phenotypes.

• Anakinra for post‑acute COVID syndrome (PACS)
• Emapalumab targeting IFNγ in sepsis driven by a specific immune endotype
• IL‑6 blockade to modulate systemic inflammation in acute cardiac events

These studies aim to restore immune balance and reduce organ damage in critically ill patients.

Research emphasizes early recognition of clinical deterioration using prognostic scores and biomarkers, with the goal of preventing full‑blown sepsis.

• suPAR‑guided clarithromycin initiation in at‑risk pneumonia patients
• qSOFA and NEWS2 scoring combined with PSP to trigger early antibiotic therapy
• Identification of high‑risk sepsis endotypes for targeted treatment

The approach integrates bedside assessment tools to accelerate therapeutic decisions.

Clinical trials address both infectious and post‑infectious lung conditions, evaluating therapies that reduce inflammation and improve respiratory function.

• Adjunctive clarithromycin to prevent sepsis in community‑acquired pneumonia
• Anakinra to alleviate persistent respiratory symptoms after COVID‑19
• Early meropenem use guided by PSP for suspected severe respiratory infection

The site combines antimicrobial and immunomodulatory strategies to enhance recovery from lung disease.

Studies focus on viral‑related complications, particularly the lingering effects of COVID‑19, and explore how controlling inflammation can improve outcomes.

• Precision trial of anakinra for post‑acute COVID syndrome
• IL‑6 inhibition with ziltivekimab to lower cardiovascular risk after viral infection
• Evaluation of immune‑modulating antibodies in virus‑driven sepsis

By targeting viral‑induced immune pathways, the hospital aims to reduce long‑term morbidity.